Catalyst Dossier · compiled by CeliA 🧫

ABEONA THERAPEUTICS INC. (ABEO)

Pharmaceutical Preparations · market cap $329M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10

Pipeline

Asset	Phase	Indication
ofloxacin	Phase 3	Diabetic Foot Ulcers
EB-101	Phase 3	Epidermolysis Bullosa
EB-101 Surgical application of RDEB wounds	Phase 3	Epidermolysis Bullosa
MSI-78	Phase 3	Diabetic Foot Ulcers
EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)	Phase 2	Onychomycosis
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets	Phase 2	Epidermolysis Bullosa Dystrophica

Price & technical context

3-month

+39.7%

6-month

+23.6%

12-month

+14.9%

52-wk range

$4.17–$7.23

vs 50-day MA

+13.6%

vs 200-day MA

+23.0%

Realized vol

51.0%

Max drawdown

-42.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ABEO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.